Skip to main content
. 2018 Jun 12;9:187. doi: 10.3389/fpsyt.2018.00187

Table 3.

Network meta-analytic relative treatment effects for efficacy and acceptability at 6 months.

graphic file with name fpsyt-09-00187-i0004.jpg

Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. For the primary outcome (attenuated positive psychotic symptoms) estimates, results are SMD (95% CI), where SMD below 0 favors the column-defined treatment. For acceptability, results are OR (95% CI), where OR < 1 favors the row-defined treatment. Significant results are in bold. The order of treatments in the diagonal is arbitrary and does not reflect ranking. ZIP, ziprasidone; NBI, needs-based interventions (including placebo); Om3, omega-3 fatty acids; FFT, family-focused therapy; ARI, aripiprazole; Dser, D-serine; CBT-F, cognitive behavioral therapy (French & Morrison protocol); RIS, risperidone.

Inline graphicComparison.

Inline graphicEfficacy (attenuated psychotic symptoms; SMD [95% CI]).

Inline graphicAcceptability (dropout; OR [95% CI]).